Recombinant von Willebrand Factor

• References

• 1 Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-525
• 2 Ginsburg D, Sadler JE. Von Willebrand disease: a database of point mutations, insertions, and deletions. Thromb Haemost 1993; 69: 177
• 3 Sadler JE, Davie EW, Hemophilia A, hemophilia B. von Willebrand disease. In: Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H. (eds). The Molecular Basis of Blood Diseases, 2nd ed. Philadelphia: Saunders; 1995: 657-700
• 4 Montgomery RR, Coller BS. Von Willebrand disease. In: Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. Philadelphia: Lippincott; 1994: 134-168
• 5 Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. J Clin Invest 1977; 60: 390-404
• 6 Koppelman SJ, van Hoeij M, Lankhof H, Schiphorst ME, Damas C, Vlot AJ, Wise R, Bouma BN, Sixma JJ. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 1996; 87: 2292-2300
• 7 Ruggeri ZM, Ware J. Von Willebrand factor. FASEB J 1993; 7: 308-316
• 8 Lethagen S. Pathogenesis, clinical picture and treatment of von Willebrand’s disease. Ann Med 1995; 27: 641-651
• 9 Paper R. Women with bleeding disorders. Presented at the 48th Annual Meeting of the National Hemophilia Foundation. 1996. San Diego; CA:
• 10 Scott JP, Montgomery RR. Therapy of von Willebrand disease. Semin Thromb Hemost 1993; 19: 37-47
• 11 Fischer BE, Schlokat U, Mitterer A, Reiter M, Mundt W, Turecek PL, Schwarz HP, Domer F. Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinent furin. FEBS Lett 1995; 375: 259-262
• 12 Schlokat U, Fischer B, Mitterer A, Falkner F, Reiter M, Grillberger L, Mundt W, Preininger A, Mohr G, Siekmann J, Turecek P, Schwarz HP, Domer F. Herstellung und Charakterisierung von rekombinantem Willebrand-Faktor. In: Scharrer I, Schramm W. (eds). 26. Hamophilie-Symposion Hamburg 1995. Berlin; Springer Verlag: 1997: 147-158
• 13 Furlan M, Robles R, Affolter D, Meyer D, Baillod P. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA 1993; 90: 7503-7507
• 14 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234
• 15 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-4244
• 16 Turecek PL, Furlan M, Lämmle B, Richter G, Gritsch H, Siekmann J, Schwarz HP. Cleavage of recombinant von Willebrand factor (vWF) by a vWF-depolymerizing protease. Blood. 1996. 88. 326a (abst)
• 17 Stoddart JH, Andersen J, Lynch DC. Clearance of normal and type 2A von Willebrand factor in the rat. Blood 1996; 88: 1692-1699
• 18 Sakariassen KS, Aarts PAMM, DeGroot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med 1983; 102: 522
• 19 Fretto LJ, Fowler WE, McCaslin DR, Erickson HP, McKee PA. Substructure of human von Willebrand factor. J Biol Chem 1986; 261: 15679-15689
• 20 Ohmori K, Fretto LJ, Harrison RL, Switzer MEP, Erickson HP, McKee PA. Electro microscopy of human factor Vlll/von Willebrand glycoprotein: Effect of reducing reagents on structure and function. J Cell Biol. 1982: 632-640
• 21 Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol 1996; 72: 341-348
• 22 Turecek PL, Gritsch H, Richter G, Auer W, Pichler L, Schwarz HP. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease. Thromb Haemost. in press
• 23 Slappendel RJ. Von Willebrand’s disease in Dutch Kooiger dogs. Vet Quart 1995; 17: 21-22
• 24 Drouet L, Roussi J, Bonneau M. et al The effect of recombinant human von Willebrand factor in pigs with severe von Willebrand’s disease. Blood 1995; 86 (Suppl. 01) 612a (abst)
• 25 Stokol T, Parry BW, Mansell PD. Factor VIII activity in canine von Willebrand disease. Vet Clin Pathol 1995; 24: 81-90
• 26 Sodetz JM, Pizzo S, McKee P. Relationship of sialic acid to function and in vivo survival of human Factor Vlll/von Willebrand factor protein. J Biol Chem 1977; 252: 5538-5546
• 27 Fischer BE, Turecek PL, Mitterer A, Schlokat U, Falkner FG, Schwarz HP, Domer F. Multimeric composition and structural analysis of a recombinant von Willebrand factor (rvWF). Thromb Haemost 1995; 73: 1166 (abst.)
• 28 Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII: C deficiency) bleeding. Blood 1982; 60: 727-730
• 29 Mertz ET. The anomaly of a normal duke’s and a very prolonged saline bleeding time in swine suffering from an inherited bleeding disease. Am J Physiol 1942; 136: 360-362